(주)바이오노트
| KRW bn | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | 2026 Q3 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 24.7 | 28.4 | 32.4 | 29.5 | 28.0 | 32.6 | 36.4 | 32.1 |
| Operating income | 2.5 | 4.7 | 6.3 | 4.8 | 0.8 | 6.3 | 8.5 | 8.0 |
| Net income | 11.1 | 4.0 | 84.5 | 17.9 | -194.0 | 41.3 | 9.1 | -65.3 |
| Cash from operations | 21.8 | 1.0 | 3.3 | 5.6 | 4.5 | 10.5 | 25.0 | 8.0 |
| Free cash flow | 17.4 | -2.4 | 0.8 | 4.9 | 3.0 | 9.8 | 23.9 | -9.1 |
| KRW bn | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 90.1 | 102.8 | 118.3 |
| Operating income | -47.0 | 12.2 | 16.7 |
| Net income | -20.5 | 55.3 | -87.5 |
| Cash from operations | -4.2 | 57.9 | 14.4 |
| Free cash flow | -8.2 | 47.5 | 6.3 |
| Gross margin | 56.7% |
| ROA | -12.8% |
| Liabilities / equity | 0.03x |
| Current ratio | 36.51x |
| FCF margin | 21.4% |
| CFO / net income | -0.23x |
| Filing | Form | ||
|---|---|---|---|
| Thu 19 Nov 2026 | |||
| Proxy Solicitation Material | DEF 14A | ||
| Notice of Shareholders' Meeting | DEF 14A | ||
| Fri 13 Nov 2026 | |||
| Quarterly Report — 2026.09 | 10-Q | ||
| Thu 12 Nov 2026 | |||
| Preliminary Consolidated Operating Results (Fair Disclosure) | 8-K | EN form | |
| Tue 10 Nov 2026 | |||
| [Amendment] Board Resolution to Convene Shareholders' Meeting | DEF 14A/A | EN form | |
| Mon 26 Oct 2026 | |||
| Record Date / Shareholder Register Closure | 8-K | ||
| Board Resolution to Convene Shareholders' Meeting | DEF 14A | ||